TriangleIntensity modulated radiation… (NCT04774419)
Intensity modulated radiation therapy (IMRT) trial for Endometrial Cancer (NCT04774419). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with stage III–IVA endometrial cancer, without measurable residual disease. Tumors must be mismatch-repair-deficient, MSI-high or POLE-mutated; POLE enrollment is capped.
The idea: dostarlimab blocks PD-1 immune suppression alongside radiation. The open group receives five radiation treatments over one week, plus four dostarlimab infusions three weeks apart and a fifth dose. The longer radiation-course arm is completed. Treatment starts 3–12 weeks after surgery; researchers assess safety and progression.
This phase 2 study plans 62 patients. Ying Liu leads at Memorial Sloan Kettering, New York; seven US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.